Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an announcement.
Shandong Xinhua Pharmaceutical has obtained regulatory approval from China’s National Medical Products Administration to change the marketing licence holder for its Galculus Bovis and Metronidazole Capsules. The approval confirms the product meets drug registration requirements and formally designates Xinhua Pharmaceutical as the new marketing authorization holder.
The change follows a September 2023 technology and holder transfer contract under which Jilin Zhongsheng Pharmaceutical agreed to transfer all MAH-related rights for the product, including manufacturing, sales and commercialization, to Xinhua Pharmaceutical. This consolidation of rights is expected to strengthen Xinhua Pharmaceutical’s control over production and marketing of the capsules, with implications for its product portfolio management and revenue streams.
The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a China-based pharmaceutical manufacturer focused on prescription drugs and related formulations. Listed in Hong Kong and the mainland, the company develops, produces and commercializes a range of medicines for the domestic market and potentially broader regional distribution.
Average Trading Volume: 1,013,518
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.71B
See more insights into 0719 stock on TipRanks’ Stock Analysis page.